Try our Advanced Search for more refined results

Federal Trade Commission v. Allergan plc et al

  1. February 20, 2019

    FTC's Teva Settlement A Sign Of Enforcement Evolution

    The Federal Trade Commission's settlement this week with Teva Pharmaceuticals further winnows the types of deals the company can sign with would-be competitors and illuminates the agency's evolving approach to cases in which drug companies are accused of colluding to delay competition.

  2. February 19, 2019

    FTC Pens New Deal With Teva On Reverse-Payment Claims

    The Federal Trade Commission said Tuesday it has reached an agreement with Teva Pharmaceuticals that would prevent the drugmaker from entering into certain reverse-payment patent settlements that can delay the availability of generic versions of drugs.

  3. April 05, 2017

    Over FTC Protest, Lidoderm Pay-For-Delay Suit Stayed

    A California federal judge on Wednesday granted Watson Laboratories Inc.'s request to pause a Federal Trade Commission pay-for-delay lawsuit over pain relief patch Lidoderm while a Pennsylvania court considers Watson's challenge to the agency's authority to bring litigation over past conduct.

  4. February 16, 2017

    Watson Wants Lidoderm Suit Stayed For Ruling On FTC Power

    Watson Laboratories Inc. asked a California federal court Wednesday to pause a renewed pay-for-delay lawsuit by the U.S. Federal Trade Commission over pain relief patch Lidoderm while a different court considers Watson's challenge to the agency's authority to bring such a suit.

  5. January 23, 2017

    Endo Settles Pay-For-Delay Suit As FTC Renews Watson Case

    Endo settled Federal Trade Commission claims Monday that it violated antitrust laws by using pay-for-delay settlements to block consumers' access to generic versions of drugs Opana ER and Lidoderm, while the agency refiled charges against Watson Laboratories for its alleged role in the scheme.